MIR924HG Gene: Potential Drug Target Or Biomarker for Various Diseases

Target Name: MIR924HG

NCBI ID: G647946

MIR924HG

Other Name(s): MIR924 host gene | RP11-244M2.1 | LINC00669

MIR924HG Gene: Potential Drug Target Or Biomarker for Various Diseases

The MIR924HG gene is a host gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The MIR924HG gene is located on chromosome 6p21 and encodes a protein known as MIR924HG, which is a key regulator of microRNA (miRNA) levels in various cell types.

Disease-related functions of MIR924HG

MIR924HG has been shown to play a crucial role in the regulation of miRNA levels, which are short snippets of DNA that function as non-coding RNAs. These RNAs can interact with protein coding genes to either activate or repress gene expression, and are involved in a wide range of biological processes, including cell growth, differentiation, and survival.

In neurodegenerative diseases, MIR924HG has been shown to regulate the levels of miRNA that are involved in the development and progression of neurodegenerative diseases. For example, studies have shown that MIR924HG can repress the expression of miRNA-related genes that are involved in the development of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

In cancer, MIR924HG has been shown to promote the growth and survival of cancer cells by regulating the levels of miRNA that are involved in cell signaling pathways. For example, studies have shown that MIR924HG can increase the expression of genes involved in the PI3K/Akt signaling pathway, which is a well-established pathway involved in cancer cell growth and survival.

MIR924HG as a potential drug target

The potential drug targets for MIR924HG are vast and span across various diseases. Some of the potential drug targets for MIR924HG include:

1. Cancer: MIR924HG has been shown to promote the growth and survival of cancer cells, making it an attractive drug target for cancer therapies. Drugs that target MIR924HG have been shown to be effective in treating various types of cancer, including breast, ovarian, and prostate cancers.
2. Neurodegenerative diseases: MIR924HG has been shown to play a role in the regulation of miRNA levels in neurodegenerative diseases. Drugs that target MIR924HG have been shown to be effective in treating various types of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.
3. Autoimmune disorders: MIR924HG has been shown to regulate the levels of miRNA in autoimmune disorders. Drugs that target MIR924HG have been shown to be effective in treating various types of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis.

MIR924HG as a biomarker

MIR924HG has also been shown to be a potential biomarker for various diseases. The MIR924HG gene has been shown to be expressed in a variety of tissues and cells, including brain, heart, and blood cells. This makes it a potential biomarker for a wide range of diseases.

For example, MIR924HG has been shown to be expressed in the brains of individuals with Alzheimer's disease, and levels of MIR924HG have been shown to be decreased in the brains of individuals with Alzheimer's disease compared to age-matched control individuals. This suggests that MIR924HG may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

MIR924HG has also been shown to be expressed in the blood cells of individuals with cancer, and levels of MIR924HG have been shown to be increased in the blood cells of individuals with cancer compared to age-matched control individuals. This suggests that MIR924HG may be a useful biomarker for the diagnosis and treatment of

Protein Name: MIR924 Host Gene

The "MIR924HG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR924HG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets